News Archive

Qualcomm Incorporated (NASDAQ:QCOM) through its wholly owned subsidiary, Qualcomm Life, Inc., today announced that the second-generation of its Capsule Vitals Plus solution has been granted 501(k) clearance from the Food & Drug Administration (FDA) and is now available for purchase. Through accurate and timely capture of medical device data and continuous monitoring of key vital signs, Capsule Vitals Plus enables integrated surveillance that moves beyond spot monitoring by capturing and analyzing data right at the bedside to support treatment decisions and care coordination.

With patient acuity levels in non-critical care on the rise and pressures to reduce length of stay, clinicians are making the transition from non-connected, episodic patient monitoring, to fully-connected integrated surveillance. This progression requires the ability to collect and analyze data, integrating clinical observations along with other contextual data types and sources to reveal patient trends directly at the bedside. The second generation Capsule Vitals Plus allows clinicians to login; associate a patient and capture their blood pressure, oxygen saturation, pulse rate and temperature; calculate an early warning score; and transmit validated data to the electronic medical record (EMR) or enterprise clinical systems directly from the patient bedside, ultimately reducing charting time from hours to minutes.

“As non-critical care environments are rapidly changing, we developed a mobile connectivity solution to increase surveillance, improve workflow and reduce patient risk,” said James Mault, MD, FACS, senior vice president and chief medical officer, Qualcomm Life, Inc. “Capsule Vitals Plus was designed by clinicians for clinicians to offer advanced usability, chartability and remote management.”